Trastuzumab containing regimens for early breast cancer
L Moja, L Tagliabue, S Balduzzi… - Cochrane database …, 2012 - cochranelibrary.com
Background Approximately one‐fifth of women who develop early breast cancer have HER2‐
positive tumours, which if untreated, have a worse prognosis than HER2‐negative tumours …
positive tumours, which if untreated, have a worse prognosis than HER2‐negative tumours …
Trastuzumab‐containing regimens for metastatic breast cancer
S Balduzzi, S Mantarro, V Guarneri… - Cochrane Database …, 2014 - cochranelibrary.com
Background Patients with breast cancer are classified as having cells that over‐express the
human epidermal growth factor receptor 2 (known as HER2‐positive) or not (HER2 …
human epidermal growth factor receptor 2 (known as HER2‐positive) or not (HER2 …
[HTML][HTML] Immune infiltrates in breast cancer: recent updates and clinical implications
MV Dieci, F Miglietta, V Guarneri - Cells, 2021 - mdpi.com
In recent decades, the increasing interest in the field of immunotherapy has fostered an
intense investigation of the breast cancer (BC) immune microenvironment. In this context …
intense investigation of the breast cancer (BC) immune microenvironment. In this context …
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates
AO Hoff, BB Toth, K Altundag… - Journal of Bone and …, 2008 - academic.oup.com
Introduction: Osteonecrosis of the jaw (ONJ) has been reported in patients treated with
bisphosphonates. The incidence and risk factors associated with this disorder have not been …
bisphosphonates. The incidence and risk factors associated with this disorder have not been …
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri, K Broglio, SW Kau, M Cristofanilli… - Journal of clinical …, 2006 - ascopubs.org
Purpose To evaluate whether hormonal receptor (HR) status can influence the prognostic
significance of pathologic complete response (pCR). Patients and Methods This …
significance of pathologic complete response (pCR). Patients and Methods This …
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)
SRD Johnston, N Harbeck, R Hegg, M Toi… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
recurrence or have distant recurrence with currently available standard therapies. However …
recurrence or have distant recurrence with currently available standard therapies. However …
[HTML][HTML] Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter …
MV Dieci, C Criscitiello, A Goubar, G Viale, P Conte… - Annals of oncology, 2014 - Elsevier
Background There is a need to develop surrogates for treatment efficacy in the neoadjuvant
setting to speed-up drug development and stratify patients according to outcome. Preclinical …
setting to speed-up drug development and stratify patients according to outcome. Preclinical …
[PDF][PDF] Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Center experience
V Guarneri, DJ Lenihan, V Valero… - Journal of Clinical …, 2006 - researchgate.net
Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The MD Anderson
Cancer Center Experience Page 1 Long-Term Cardiac Tolerability of Trastuzumab in Metastatic …
Cancer Center Experience Page 1 Long-Term Cardiac Tolerability of Trastuzumab in Metastatic …
[PDF][PDF] Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the …
V Guarneri, A Frassoldati, A Bottini… - Journal of clinical …, 2012 - researchgate.net
Purpose This is a noncomparative, randomized, phase II trial of preoperative taxane-
anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus …
anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus …
[HTML][HTML] Evolution of HER2-low expression from primary to recurrent breast cancer
F Miglietta, G Griguolo, M Bottosso, T Giarratano… - NPJ breast …, 2021 - nature.com
About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …
targeted by new antibody-drug conjugates. The main aim of this study is to describe the …